Organic anion transporters (OATs) and organic anion-transporting polypeptides (OATPs), encoded by a number of solute carrier (SLC)22A and SLC organic anion (SLCO) genes, mediate the absorption and distribution of drugs and other xenobiotics. The regulation of OATs and OATPs is complex, comprising both transcriptional and post-translational mechanisms. Plasma membrane expression is required for cellular substrate influx by OATs/OATPs. Thus, interest in post-translational regulatory processes, including membrane targeting, endocytosis, recycling and degradation of transporter proteins, is increasing because these are critical for plasma membrane expression. After being synthesized, transporters undergo N-glycosylation in the endoplasmic reticulum and Golgi apparatus and are delivered to the plasma membrane by vesicular transport. Their expression at the cell surface is maintained by de novo synthesis and recycling, which occurs after clathrin-and/or caveolin-dependent endocytosis of existing protein. Several studies have shown that phosphorylation by signalling kinases is important for the internalization and recycling processes, although the transporter protein does not appear to be directly phosphorylated. After internalization, transporters that are targeted for degradation undergo ubiquitination, most likely on intracellular loop residues. Epigenetic mechanisms, including methylation of gene regulatory regions and transcription from alternate promoters, are also significant in the regulation of certain SLC22A/SLCO genes. The membrane expression of OATs/OATPs is dysregulated in disease, which affects drug efficacy and detoxification. Several transporters are expressed in the cytoplasmic subcompartment in disease states, which suggests that membrane targeting/internalization/recycling may be impaired. This article focuses on recent developments in OAT and OATP regulation, their dysregulation in disease and the significance for drug therapy.
Introduction
The solute carrier (SLC) superfamily of transporters contains over 300 members across 52 families and mediates the cellular influx of a wide range of endobiotics. It is now apparent that certain SLC transporters also participate in the transmembrane movement of exogenous chemicals. Two important subfamilies of human SLC transporters that modulate drug and xenobiotic uptake are the organic anion transporters (OATs, encoded by the SLC22A6-22A11 genes) and the organic anion transporting polypeptides [OATPs, encoded by SLC organic anion (SLCO) genes] ( Koepsell and Endou, 2004; Roth et al., 2012) .
A number of factors influence OAT and OATP transporter function. Polymorphic SLC22A anion transporter and SLCO genes encode transporter variants that may have altered transporter activity (Zhou et al., 2016) . In addition, because some OAT and OATP transporters have broad substrate specificities, there is the potential for inhibitory pharmacokinetic interactions involving drug uptake into cells. However, it is now clear that the regulation and expression of OAT and OATP transporters are critical determinants of the influx of chemicals into cells. In this regard, an increasing number of reports have indicated that post-translational mechanisms, including the trafficking of OATs and OATPs to and from the plasma membrane, are important processes that influence substrate transport. This article focuses primarily on the regulation and trafficking mechanisms of human OATs and OATPs and how these modulate transporter function in health and disease.
SLC transporter multiplicity, structure and function
The OATs are a subgroup of the larger SLC22A gene family that includes transporters for organic anions, organic cations and peptides. Of the nine human OATs, OATs 1-4 and OAT6 have been found to mediate the uptake of drugs and toxic chemicals as well as endobiotics into cells (Table 1) , while Table 1 Human OAT and OATP transporters that modulate drug and xenobiotic influx into cells OATP-H digoxin Mikkaichi et al. (2004) the other members transport endobiotic solutes such as steroid conjugates, eicosanoids and small polar molecules (Nigam et al., 2015) . Similarly, 11 human OATPs have been identified and classified into six subfamilies based on amino acid identity. There are five human OATPs that mediate cellular xenobiotic and endobiotic uptake (OATPs 1A2, 1B1, 1B3, 2B1 and 4C1; Table 1 ), while the remaining transporters participate in the uptake of thyroid and peptide hormones, oestrogens and prostanoids (Roth et al., 2012, and references therein) . With the exception of OAT4, most xenobiotictransporting human OATs and OATPs have rodent orthologues. However, gene duplication has resulted in five rodent genes that correspond to OATP1A2 (Oatp1a1 and Oatps 1a3-1a6), and the rodent Oatp1b2 corresponds to human OATP1B1/OATP1B3 (Roth et al., 2012) . Species differences in OAT/OATP multiplicity and substrate specificity are important considerations when extrapolating findings on the regulation of rodent transporters to humans (Roth et al., 2012; Hagenbuch and Stieger, 2013; Nigam et al., 2015) . (Roth et al., 2012; Koepsell, 2013; Zhou et al., 2016) . The structures of OAT/OATP transporters contain several critical regions that control function, subcellular localization and trafficking mechanisms. From 3D models of OATs and OATPs, a 12 transmembrane domain (TMD) structure has been predicted (Wolff et al., 1997; Hagenbuch and Meier, 2004; Koepsell and Endou, 2004) . OATs have a large extracellular loop between TMDs 1 and 2, while OATPs have a similar loop between TMDs 9 and 10. Both types of transporters have a number of smaller extracellular and intracellular loops between other TMDs, and the carboxyl and amino terminal regions are intracellular (Meier-Abt et al., 2005; Hong, 2014) . While crystal structures for mammalian OAT/OATP transporters are not yet available, partial structures for the related PepT1/PepT2 transporters (SLC15A1/SLC15A2) have been reported (Beale et al., 2015) . In addition, a high-resolution structure has been reported for the bacterial transporter LacY (Abramson et al., 2003) ; this has been used in structural predictions for mammalian SLC transporters. Importantly in the context of post-translational regulation, potential N-glycosylation and other regulatory motifs have been identified in several OAT/OATP transporter regions (Figure 1 ).
Tissue, cell and species-specific expression are also important factors in interpreting the roles of OAT/OATP transporters in xenobiotic disposition. OATs 1-3 are localized at the basolateral membrane of renal proximal tubular cells where they mediate the urinary secretion of drugs and toxins (Lopez-Nieto et al., 1997; Sekine et al., 1997; Cha et al., 2001) . OAT1 is also found at the apical membrane of the choroid plexus and in brain, placenta and skeletal muscle, OAT2 is expressed at the sinusoidal membrane of hepatocytes and kidney, OAT3 is highly expressed in kidney and several brain regions and OAT4 is expressed in placental synctiotrophoblasts (Ugele et al., 2003) and at the apical membrane of the renal proximal tubule (Ekaratanawong et al., 2004) . While information on the tissue distribution of human OAT6 is sparse, the murine Oat6 is expressed in olfactory mucosa and the testis (Monte et al., 2004; Schnabolk et al., 2006) . OATP1A2 is located in hepatic cholangiocytes, brain endothelial cells and at the apical membranes of the distal nephron and retinal epithelial cells (Bronger et al., 2005; Lee et al., 2005; Glaeser et al., 2007; Chan et al., 2015b) . OATPs 1B1 and 1B3 are mainly localized to the basolateral membrane of hepatocytes (Konig et al., 2000b; Abe et al., 2001; Kullak-Ublick et al., 2001; Cui et al., 2003) . OATP2B1 protein is widely expressed at the basolateral membrane of hepatocytes and placental syncytiotrophoblasts, the apical membrane of enterocytes, in skeletal muscle and in endothelial cells of the blood-brain barrier St-Pierre et al., 2002; Kobayashi et al., 2003; Bronger et al., 2005; Knauer et al., 2010) . OATP4C1 is found at the basolateral membrane of the renal proximal tubule and in fetal liver and kidney (Mikkaichi et al., 2004; Bleasby et al., 2006) .
Figure 1
Predicted secondary structures of human (A) OAT1 and (B) OATP1A2. Both transporters contain 12 TMDs, intracellular N-and C-termini and several intracellular and extracellular loops. Asparagine residues that are subject to N-glycosylation (G) are shown in the extracellular loops between TMDs 1 and 2 of OAT1 and between TMDs 3/4 and 9/10 of OATP1A2 (Tanaka et al., 2004a; Yao et al., 2012) . Lysine residues in OAT1 that are subject to ubiquitination in the intracellular loop between TMDs 6 and 7 are shown (U; Li et al., 2013) . Cysteine residues, with the potential for involvement in oligomerization, in OATP1A2 are shown as the green ellipses in the extracellular loop between TMDs 9 and 10. The yellow box shows the PDZ domain in the C-terminal region of OATP1A2.
Transcriptional regulation of SLC and SLCO genes
Basal expression of SLC22A and SCLO genes
In rodent liver and kidney, several SLC22A/SLCO mRNAs are expressed at a low level and then increase with age, while others are expressed at similar levels in neonatal and adult animals Klaassen and Aleksunes, 2010; Hou et al., 2014; Fattah et al., 2015) . Information on the ontogenesis and regulation of human OAT and OATP transporters is limited. Human OATP1A2 mRNA was expressed in 110 normal placenta from 6 weeks of gestation and was highest in term placentas (Loubière et al., 2010) . At the protein level, OATP1A2 was localized to villous cytotrophoblasts, syncytiotrophoblasts and extravillous trophoblasts with multiple immunoreactive bands indicative of several N-glycosylated forms. Similarly, human OATP1B1 and OATP1B3 proteins were quantified in 80 paediatric livers spanning an age range from 9 days to 12 years. Expression of both transporters varied over a several-fold range (Thomson et al., 2016) . OATP1B3 expression at birth was high, followed by a decline and then increased in preadolescence, whereas OATP1B1 expression appeared to be somewhat lower in livers from younger subjects. In another study, hepatic OATP1B1 and OATP1B3 mRNA expression was lower in paediatric subjects than in adults, while intestinal OATP2B1 mRNA was higher in neonates (Mooij et al., 2014) . Using a proteomics approach the same group went on to report similar levels of OATPs 1B1 and 2B1 expression across age ranges in 25 human livers (Mooij et al., 2016) . Very recently, Thomson et al. (2016) showed that glycosylated OATP1B3 was higher in children younger than 3 months, decreased by 6 years of age, followed by a further increase with age. These findings are consistent with age-related maturation of post-translational trafficking to the plasma membrane.
In rodents, gender dimorphisms implicate the endocrine regulation of some SLC22A/SLCO transporter genes via the hypothalamic-pituitary-gonadal axis, mediated by androgen and oestrogen, and growth hormone pulsatility (Buist et al., 2003; Cheng et al., 2005) . Similar mechanisms control the gender-specific expression of hepatic cytochrome P450 (CYPs) and other genes that mediate endobiotic and xenobiotic biotransformation in rodents (Waxman and O'Connor, 2006) . To date, there is little information on gender-specific regulation of human OAT/OATP transporters, which is restricted to reports that the renal clearance of drugs like methotrexate and amantadine is greater in males than in females (Wong et al., 1995; Godfrey et al., 1998) . It is noteworthy that one study conducted in primary hepatocytes implicated the Jak-Stat5 pathway in the regulation of human OATP1B3 by growth hormone and prolactin (Wood et al., 2005) . Because this pathway regulates gender-specific CYPs in rodent liver (Waxman and O'Connor, 2006) , it is feasible that pituitary hormones may also contribute to genderspecific transporter function in humans.
Transcriptional activation of SLC22A and SLCO genes
The activation of SLC22A/SLCO gene transcription by exogenous drugs and chemicals has been studied extensively, principally in rodents. The pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are nuclear receptors that regulate the induction of CYPs, other biotransformation enzymes and transporters that facilitate the detoxification and clearance of drugs and other foreign chemicals (Willson and Kliewer, 2002) . Retinoic acid receptors, the farnesoid X receptor (FXR) and the liver X receptor, are related nuclear receptors that are activated by vitamin A, bile acids and oxysterols respectively. These receptors also regulate mammalian CYPs, phase II enzymes and transporters in response to dietary micronutrients and in certain disease states (Chen et al., 1995; Nigam et al., 2015) . In contrast, the aryl hydrocarbon receptor (AhR) is a cytoplasmic basic-helix-loop-helix transcription factor that binds polycyclic aromatic hydrocarbons and related planar aromatic ligands to activate target genes (Denison et al., 1988) . The AhR also regulates CYPs of family 1, phase II conjugation genes and transporters to enhance the removal of foreign chemicals from the organism (Bock, 2014) .
Unlike their rodent counterparts, few human SLC22A or SLCO genes are activated by nuclear receptors or the AhR (Rausch-Derra et al., 2001; Staudinger et al., 2001; Aleksunes and Klaassen, 2012 ). An exception is OATP1A2 that is upregulated in human breast cancer cells by the PXR ligand rifampin (Jigorel et al., 2006; Meyer zu Schwabedissen et al., 2008) . Increased OATP1A2 expression could contribute to breast cancer pathogenesis because increased influx of the substrate oestrone 3-sulfate could drive tumour cell proliferation (Meyer zu Schwabedissen et al., 2008) . In contrast, the CAR ligand phenobarbital down-regulated OATP1B3 and OAT2 in human liver slices (Jigorel et al., 2006) , and the retinoic acid receptor ligand all-trans-retinoic acid down-regulated OATP1B1 and OATP2B1 mRNAs and immunoreactive proteins in primary human hepatocytes (Le Vee et al., 2013) . Exposure of human liver-derived cells to AhR ligands repressed OATP1B1, OATP1B3 and OAT2 mRNAs (Jigorel et al., 2006; Le Vee et al., 2015) . In contrast, the human SLCO4C1 promoter was activated by the AhR ligand 3-methylcholanthrene via a xenobiotic-response element in the 5 0 -flank (Toyohara et al., 2009) . Together, there is emerging evidence that exposure to nuclear receptor or AhR ligands alters the expression of several OATs and OATPs. However, the detailed underlying mechanisms have not been fully elucidated.
Liver-specific transcription factors are important regulators of human SLC22A and SLCO genes. Hepatocyte nuclear factor-1α (HNF1α) activates the expression of OAT1, OAT3, OAT5, OATP1B1 and OATP1B3 in human liverderived cells via putative HNF1α binding elements in the proximal promoters (Jung et al., 2001; Kikuchi et al., 2006; Saji et al., 2008; Klein et al., 2010) . Another liver-specific nuclear receptor -the transcription factor HNF4α -also transactivated the human OAT1, OAT2, OATP1B1, OATP1B3 and OATP2B1 promoters (Popowski et al., 2005; Kamiyama et al., 2007; Ogasawara et al., 2007; Knauer et al., 2013; Yamashita et al., 2014) . Evidence has been otained that disruption of HNF function in some types of liver disease suppresses several transporters in cells (Geier et al., 2003; Vavricka et al., 2004) .
Epigenetic mechanisms contribute to tissue-specific expression of transporters (Kikuchi et al., 2006; Chen et al., 2013) . Nucleotides around the transcription startsites in human SLC22A6 and SLC22A8 were found to be extensively methylated in liver, but not kidney, which could account for the absence of these transporters from liver (Jin et al., 2012; Imai et al., 2013) . Indeed, direct evidence of a role for methylation in silencing of SLCO1B3 in cancer cell lines has been obtained from experiments in which the DNA methyltransferase inhibitor 5-aza-2 0 -deoxycytidine restored expression ( Figure 2A ; Ichihara et al., 2010; Han et al., 2013) .
Some human transporter variants are transcribed from SLC genes under the control of alternate promoters to give rise to tissue-specific expression (Knauer et al., 2013) . A truncated OATP2B1 variant that lacks the N-terminal 22 amino acids was found to be the predominant form of the transporter in liver, whereas the full-length OATP2B1 is the dominant form in intestine (Knauer et al., 2013) . However, whereas the basal transcription factor specificity protein-1 activated constitutive expression of the fulllength OATP2B1, liver-specific expression of the truncated variant was regulated by HNF4α (Knauer et al., 2013) . Both the full-length and truncated forms of OAT2B1 were expressed at the cell surface and mediated substrate transport. In summary, there are several important examples in which human transporter genes are regulated by exogenous chemicals and epigenetic mechanisms that lead to altered function.
Post-translational processing of SLC transporters
Many of the early studies dealing with OAT and OATP expression were focussed at the mRNA level with fewer reports in which transporter protein expression was evaluated. It is emerging that a number of posttranslational regulation mechanisms mediate the trafficking of mature transporters to the plasma membrane, the endocytosis of the proteins from the membrane, and their recycling back to the cell surface. In general, posttranslational processes appear to be of prime importance in controlling the transporter-assisted influx of drugs and other chemicals into cells.
Transporter N-glycosylation
The expression of mature SLC transporters at the plasma membrane is essential for the transport of drugs and other xenobiotics into cells. Several post-translational mechanisms interact to regulate the targeting of nascent transporter proteins to, and their retrieval from, the plasma membrane ( Figure 3 ). Newly synthesized proteins traverse the endoplasmic reticulum (ER) and Golgi apparatus where they are folded and undergo covalent modification; incorrectly folded proteins are degraded by the 26S proteasome (Banerjee, 2012) . A key quality control and membrane Figure 2 (A) Tissue-and cell-specific transcriptional regulation of full length OATP1B3 in kidney, and the truncated cancer-specific OATP1B3 isoform (cs-OATP1B3) in liver. Green and red boxes indicate the activation and repression of transcription via epigenetic mechanisms respectively. cs-OATP1B3 transcription is activated in some tumour cell types (red boxes) and repressed in others (green boxes). (B) CYP7A1 converts cholesterol to bile acids that are ligands for the FXR. FXR-RXR dimers activate a number of genes, including SHP1. Over-production of bile acids in cholestasis suppresses SHP and the liver-specific transcription factor HNF4α; down-regulation of HNF4α also suppresses HNF1α. Loss of both HNF isoforms decreases the expression of OATP1B1 and OATP1B3 that mediate bile acid influx and CYP7A1 to suppress further bile acid production targeting process is N-linked glycosylation on asparagine residues (Rosnoblet et al., 2013) . Here oligosaccharyltransferase transfers mannose-containing oligosaccharides from lipid-linked precursors on the ER membrane onto suitable asparagine (N) residues in N-X-S/T motifs (where X is any residue, S/T is serine or threonine; Aridor, 2007) . Further processing of the glycoconjugate in the trans-Golgi removes three terminal glucose residues and one or more mannose residues prior to reglycosylation with N-acetylglucosamine, galactose, and sialic acid . After these editing steps the proteins are packaged for transport to the plasma membrane (Traub and Kornfeld, 1997; Opat et al., 2001) .
Some OATs and OATPs have been shown to undergo extensive N-glycosylation on asparagine residues in their large extracellular loops. Studies have shown that mutagenesis of individual asparagine residues decreased human OAT1 and OAT4 activity but had minimal effects on plasma membrane expression (Tanaka et al., 2004a; Zhou et al., 2005) . Unglycosylated proteins were retained intracellularly and were not well expressed at the cell surface . Replacement of multiple asparagine residues was required for impaired membrane targeting of human OAT4. Similarly, three asparagine residues located at positions 134, 503 and 516 in the extracellular loops between TMDs 1/2 and 9/10 were important for the N-glycosylation and plasma membrane expression of OATP1B1 (Yao et al., 2012) . Mutagenesis of four predicted N-glycosylation sites in rat Oatp1 (N62, N124, N135 and N492) also prevented membrane targeting as well as substrate transport (Lee et al., 2003) . In contrast, membrane targeting was prevented in some naturally occurring OATP1A2 variants in which individual asparagine residues were replaced. Thus, the cell surface expression of the N135I and, to a lesser extent N128Y, variants of OATP1A2 was decreased; these residues are located in the first external loop between TMDs 1 and 2 (Figure 1 ; Lee et al., 2005) . Taken together these findings suggest that, at least in the case of some transporters, N-linked glycosylation that enables adequate targeting to the plasma membrane may still occur if only one of the asparagine residues is replaced.
Oligomerization
Oligomerization enables egress of transporters from the ER/Golgi and targeting to the plasma membrane (Race et al., 1999; Hong et al., 2005) . The large extracellular loop between TMDs 9 and 10 is common to all OATPs and contains ten conserved cysteine residues (Hänggi et al., 2006) . Disulfide bond formation appears to be important for the oligomerization of some transporters. Thus, mutagenesis of the cysteine residues in OATP2B1 led to misprocessing and intracellular accumulation (Hänggi et al., 2006) . Likewise, Figure 3 Overview of potential pathways of OAT/OATP transporter trafficking. N-glycosylation in the ER-Golgi apparatus is followed by vesicular delivery to the plasma membrane. Subsequent internalization from the plasma membrane occurs via clathrin-coated pits and caveolae that deliver transporters to the early endosome. From the early endosome evidence suggests that certain transporters could be delivered to the late endosome for lysosomal degradation, or to the recycling endosome and the Golgi apparatus for targeted delivery back to the plasma membrane. Individual OAT/OATP transporters have been detected in each of the subcellular locations indicated. However, each pathway has not been uniformly established for all transporters. Greater mechanistic detail along each of the proposed pathways is also required. Key: vertical blue bars indicate unglycosylated transporter monomers in the Golgi apparatus; G indicates N-glycosylated transporter monomers.
the simultaneous replacement of 13 cysteine residues in the C-terminal region of murine Oat1 impaired trafficking to the cell surface and led to almost complete loss of function (Tanaka et al., 2004b) . In some cases residues other than cysteine may participate in oligomerization. Recently, Ni et al. (2017) implicated G393 in the putative TMD8 of OATP1B1 in oligomerization, although a role for secondary disulfide bond formation was suggested from findings with the reducing agent β-mercaptoethanol, which altered the apparent molecular size of the transporter. Cysteine residues were not implicated in the oligomerization of human OAT1 (Duan et al., 2011) . Instead, a short peptide corresponding to TMD6 of the transporter, which does not carry cysteine residues, was able to prevent oligomerization. Thus, disulfide bond formation is not implicated in the oligomerization and delivery of all OATs/OATPs to the cell surface.
Critical motifs and amino acids in OATs/OATPs that influence membrane targeting
Although underexplored, other regions in OATs and OATPs may regulate the maturation and delivery of the transporters to the plasma membrane. There are six conserved glycine residues in OAT4 across multiple species of which two residues, at positions 241 and 400 in TMD5 and TMD8, were found to be critical for plasma membrane targeting (Zhou et al., 2004) ; these residues could form part of the translocation pathway for substrate access. Naturally occurring coding region variants of OAT4, especially L29P and T392I in TMDs 1 and 8, exhibited greatly decreased plasma membrane expression (Zhou et al., 2010) . Alaninescanning mutagenesis of TMD11 in OATP1B1 identified 7 critical amino acid residues for plasma membrane expression and function (Hong et al., 2015b) . It would now be of interest to evaluate the role of the analogous residues in other OATPs to elucidate the molecular mechanisms underlying the loss of membrane expression.
Pronounced decreases in plasma membrane expression were noted for several natural OATP1A2 variants encoding the amino acid changes E184K, D188N and D288N (in intracellular loops) and T259P in putative TMD6 (Zhou et al., 2013) . These findings suggest that negatively charged acidic residues (E and D) in intracellular loops are important. It is feasible that these residues are involved in ionic or electrostatic interactions with positively charged or polar residues in adjacent intracellular loops. Residues in TMD6 in OATP1A2 were evaluated systematically and several were found to have multiple regulatory roles. The subregions spanning residues 245-248 and 261-266 influenced protein trafficking and quality control as well as substrate binding (Chan et al., 2015a) . Substrate transport function was lost when these residues were replaced by alanine, but not when the other TMD6 residues were replaced. Total and plasma membrane expression of OATP1A2 mutants was evaluated in HEK293 cell lysates. In the cases of the W245A and W246A mutants, plasma membrane expression was impaired but total expression was unchanged. Mutagenesis of the other residues in the TMD6 subregions decreased total and cell surface expression. These findings implicate the two tryptophan residues in the orientation and stability of OATP1A2 at the plasma membrane.
Vesicular delivery of transporters to the cell membrane
Membrane vesicles deliver proteins from the ER-Golgi to the plasma membrane. The coat protein clathrin has an essential role in the assembly of vesicles and the packaging of cargo in the trans-Golgi. Vesicles and their cargo are relocated to their cellular destinations by diffusion or along cytoskeletal cables consisting of microtubules or actin under the action of molecular motors (Hammer and Wu, 2002) . Molecular motor proteins from the kinesin and dynein families utilize ATP to guide vesicles through the cytoplasm (Derby and Gleeson, 2007) . The tethering of a vesicle at its target is then mediated by transmembrane soluble N-ethylmaleimide-sensitive factor attachment receptors (SNAREs; Söllner et al., 1993) .
Unloading of cargo proteins is facilitated by interactions with chaperone proteins at the destination. In this regard, postsynaptic density 95/disc-large/zona occludens (PDZ) proteins dock at PDZ modules (S/T-X-Y, where S/T is serine or threonine, X is any amino acid and Y is a hydrophobic residue) in cargo proteins, including a number of OAT/OATP transporters (Kato et al., 2004; Ye and Zhang, 2013) . In early studies a peptide corresponding to the C-terminal 16 amino acids of rat Oatp1a1 was used in the affinity-isolation of potential interacting proteins from rat liver cytosol. Using protein mass fingerprinting PDZK1 was confirmed as a major interacting protein (Wang et al., 2005 , 2008) . Thus, PDZ proteins could also play a role in determining the cell-specificity of the targeting of certain transporters to the plasma membrane. The role of PDZK1 in determining the apical location of Oatp1a in intestinal cells has been established using pdzk1-null mice (Sugiura et al., 2010) . The kinesins KifC1 and KifC3 are associated with Oatp1a1-containing vesicles in normal mouse liver (Wang et al., 2014) . Vesicles from pdzk1-null mice express a different profile of motor proteins, with increased KifC3 and dynein expression but decreased KifC1 and Kif5B resulting in an altered cellular distribution of Oatp1a1 (Wang et al., 2014) . Thus, PDZK1 appears to regulate intracellular trafficking of the transporter by recruiting specific motors to Oatp1a1-containing vesicles (Wang et al., 2014) . Whether there is a direct interaction between the Oatp1a1 cytoplasmic domain and motor proteins remains to be established (Wang et al., 2014) . Provision of analogous information for human OAT/OATP transporters would be of considerable interest.
Regulation of transporter endocytosis
Transporters undergo endocytosis from and recycling back to the plasma membrane . Modulation of these processes enables the fine-tuning of plasma membrane expression in rapid response to a range of exogenous stimuli BJP M Murray and F Zhou . Internalization of proteins from the plasma membrane occurs by clathrin-dependent and caveolin-dependent pathways (Appelqvist et al., 2013 ; Figure 3 ). Transporter proteins may be internalized into clathrin-coated pits that then pinch off from the plasma membrane and form clathrin-coated vesicles. Alternately, proteins enter caveolae, which are submicroscopic structures derived from lipid-rich regions of the plasma membrane (Parton and del Pozo, 2013) . Protein-containing clathrin vesicles and caveolae migrate to the early endosome where they undergo initial sorting before transfer to recycling or late endosomes (Parton and del Pozo, 2013) .
Clathrin-dependent endocytosis promoted the internalization of OAT1, OAT3 and OAT4 . Similarly, OATP1B1 was internalized and found within recycling endosomes in a clathrindependent pathway, like those described for OATP2B1 and OATP1A2 (Köck et al., 2010; Hong et al., 2015a; Chan et al., 2016) . In contrast, in human HEK-293 cells, OAT3 was found to be colocalized with the lipid raft-associated protein caveolin 1 (Srimaroeng et al., 2013) , OAT4 and caveolin-1 were colocalized in cultured human placental trophoblasts (Lee et al., 2008a) and caveolin-3 and Oat1 were colocalized in rat kidney (Kwak et al., 2005a; Kwak et al., 2005b) . Thus, at present, the findings indicate that both clathrin and caveolin-dependent pathways may mediate the internalization of certain OAT, but not OATP, transporters.
Phosphorylation mediates transporter internalization
Phosphorylation by PKC and other kinases modulates subcellular trafficking, turnover and internalization of transporters. At steady state the cellular distribution of OAT1 favoured cell surface expression but PKC enhanced OAT1 retrieval from the cell membrane without affecting recycling . Ligands such as angiotensin II and parathyroid hormone accelerate the internalization of OATs by activating PKC Li et al., 2009) . PKC has been found to have analogous roles in the trafficking of OATP1A2, OATP1B1, OATP1B3 and OATP2B1 internalization and recycling (Köck et al., 2010; Powell et al., 2014; Hong et al., 2015a) .
Rab GTPases are molecular switches that exist as active and inactive forms depending on the binding of GTP or GDP (Chua and Tang, 2015) . In conjunction with the SNARE proteins that tether vesicles to target membranes, and the microtubule-dependent motors, Rab GTPases regulate multiple aspects of vesicle trafficking (Howell et al., 2006) . Rab GTPases are also important regulators of endocytosis and subsequent trafficking events. The localization of individual Rab GTPases in subcellular compartments and organelles ensures the correct targeting and delivery of cargo proteins to their destinations. Thus, Rab5 is associated with clathrin-mediated endocytosis and is found along with Rab4 and Rab11 on recycling endosomes (Dinneen and Ceresa, 2004) . Rab4 has also been shown to interact with the motor protein Kif3 (Imamura et al., 2003) and the t-SNARE syntaxin-4 (Li et al., 2001) . This probably enables the fusion of vesicles with the recycling endosome and facilitates the transfer of cargo proteins such as transporters back to the cell surface. Late endosomes are enriched in Rabs 7 and 9 where they promote trafficking to lysosomes and the Golgi respectively.
Like PKC, casein kinase-2 (CK2) also controls the expression and function of OATP1A2 at the plasma membrane by regulating subcellular trafficking and stability. Both kinases decreased the expression of OATP1A2 at the cell surface by accelerating clathrin-dependent endocytosis (Zhou et al., 2011; Chan et al., 2016) . Recently, these actions have been linked to interactions with particular Rabs. The colocalisations of OATP1A2 with Rabs 4, 8 and 9 were regulated by CK2. This implicates the kinase in the movement of OATP1A2 between subcellular locations, including from the late endosomes to the trans-Golgi network, the rapid transfer to the recycling endosome and the transport of newly synthesized protein from the transGolgi network to the plasma membrane (Chua and Tang, 2015; Chan et al., 2016) .
Interestingly, unlike OATP1A2, internalized OATP1B1 was found to be colocalized with the early endosomal and recycling endosomal marker Rab11 following PKC activation (Hong et al., 2015a) . This raises the possibility that particular OAT/OATP transporters interact with different Rabs in cells. In contrast to the down-regulatory actions of PKC and CK2, activation of the atypical PKCζ isoform was found to upregulate basolateral OAT transport (Barros et al., 2009) . It would now be important to test whether the posttranslational regulation of other OATs/OATPs is similar.
OATs and OATPs contain multiple potential phosphorylation sites in intracellular loops and in the carboxyl terminus . However, evidence for direct phosphorylation at these predicted PKC consensus sites has not been obtained, which suggests that PKC, and possibly also CK2, acts indirectly as a trafficking regulator. It would now be of interest to determine whether the regulatory actions of phosphorylation are mediated by caveolins (Kwak et al., 2005a) , or other mediators of transporter endocytosis.
Transporter ubiquitination
Conjugation of the small polypeptide ubiquitin with lysine residues of OAT transporters is a major sorting signal for incorporation into late endosomes via clathrin-dependent internalization. Ubiquitination requires the coordinated action of three enzymes: The ubiquitin-activating E1 enzyme that catalyzes the formation of a thioester bond between its active cysteine and Gly 76 at the carboxyl-terminus of ubiquitin, transfer of activated ubiquitin to the ubiquitinconjugating E2 enzyme and the E3 ubiquitin-protein ligases that generate isopeptide bonds between the Gly 76 of ubiquitin and the ε-amine of a lysine residue on the target substrate (Piper et al., 2014) . PKCα has been shown to regulate OAT1 ubiquitination as well as internalization, and promotes proteasomal and lysosomal degradation 2012; Li et al., 2013) . A critical step preceding internalization is ubiquitination on Lys 297 , Lys 303 and Lys 315 in the large intracellular loop between TMDs 6 and 7 (Li et al., 2013) . OAT1 mutants with multiple lysines that were simultaneously mutagenized to arginine were resistant to PKC-induced ubiquitination and internalization (Li et al., 2013) . The intracellular loops in OATPs between TMDs 6/7
Trafficking mechanisms for OATs and OATPs BJP also contain several lysine residues that are potential ubiquitination sites. Therefore, comparative studies of the involvement of ubiquitination in the degradation of other OATs/OATPs after internalization are now warranted.
Regulation of OAT/OATP transporters in disease states
Alterations in the expression and function of SLC drug transporters have been reported to occur in several disease states. This can have a significant impact on drug disposition and the efficacy and toxicity of drugs used in treatments, because impaired plasma membrane targeting of transporters prevents drug influx. Detailed mechanisms that account for dysregulated transporter expression in pathological states are often lacking. However, important information is beginning to emerge in some syndromes.
Cancer and OAT/OATP dysregulation
Dysregulated trafficking occurs in cancer (Howell et al., 2006) . Compared with normal tissue the expression of OATs and OATPs is dysregulated in tumour tissues and many tumour cell lines (Wlcek et al., 2011; Brenner et al., 2015) . In some cancers expression is increased. For example, OATP1A2 protein expression was almost 10-fold greater in patients with breast cancer, although the intracellular distribution was found to be cytoplasmic as well as at the cell membrane (Meyer zu Schwabedissen et al., 2008) . While normally restricted to the liver, OATP1B1 was found to be overexpressed in tumours of the colon, lung, breast, prostate, ovary and pancreas Muto et al., 2007; Hamada et al., 2008; Lee et al., 2008b) . In contrast, OATP1B1 expression in hepatocellular carcinoma has been reported to be unchanged from control in one study, and decreased in two others (Vavricka et al., 2004; Vander Borght et al., 2005; Tsuboyama et al., 2010) . OATP1B3 expression was increased in colorectal tumours, but again the distribution was cytoplasmic (Lee et al., 2008b) . Some OATPs have been proposed to be novel biomarkers of tumour progression (Brenner et al., 2015) . In breast tumours, OATP2B1 expression increased with tumour grade (Al Sarakbi et al., 2006) ; OATP2B1 was also increased in thyroid cancer, glioma and in around half of prostate and testicular cancers (Bronger et al., 2005; Pressler et al., 2011) . OATP2B1 overexpression could increase uptake of the substrate oestrone 3-sulfate into ER-positive breast tumour cells and could contribute to tumourigenesis by enhancing proliferation (Matsumoto et al., 2015) . The redistribution of transporter protein away from the plasma membrane to the cytoplasmic region has been observed in several types of tumours and could be pertinent for disease pathogenesis (Lockhart et al., 2008; Meyer zu Schwabedissen et al., 2008; Lee et al., 2008b) .
Apart from altered trafficking, there may be dysregulation of transcriptional and epigenetic mechanisms in tumours. Cancer-specific variants of OATP1B3 arise from an altered transcription start site and alternative promoter located in intron 2 (Nagai et al., 2012; Imai et al., 2013) . The variants contain a modified exon 1 that encodes a different Nterminal sequence and alters post-translational processing.
It is feasible that the loss of the N-terminal region alters the transporter topology, which may impair membrane targeting and lead to cytoplasmic accumulation . It has been suggested that the cancer-specific OATP1B3 variant, but not wild-type OATP1B3, is activated in hypoxia, which could facilitate the uptake of typical OATP1B3 substrates, such as the anticancer agents methotrexate and paclitaxel, into tumour cells . DNA methylation-dependent gene silencing of wild-type OATP1B3 has been reported to occur in several cancer cell lines (Ichihara et al., 2010) , and could augment the activation of the cancer-specific variant in hypoxia. It is now important to understand the mechanisms underlying OAT/OATP dysregulation in cancer and how this relates to tumour grade and contributes to treatment optimization.
Inflammatory diseases and cytokine activity dysregulate OAT/OATP transporters
Human studies are consistent with roles for proinflammatory cytokines in dysregulation of OAT/OATP transporters. Hepatic OATP1B1 was reduced in patients with primary sclerosing cholangitis (Oswald et al., 2001) , while OATP2B1 was increased in ileal and colonic tissue from patients with Crohn's disease or ulcerative colitis (Wojtal et al., 2009) . OATP2B1 expression in human placental samples collected from preterm and term pregnancies that were diagnosed with bacterial chorioamnionitis infection was decreased to~50% of gestational age-matched controls from pregnancies with no obstetric complications (Petrovic et al., 2015) . mRNAs encoding the pro-inflammatory cytokines IL-6, IL-1β and TNF-α were increased to 2.5-to 3-fold of control in preterm placentas with infection (Petrovic et al., 2015) . Treatment of primary human hepatocytes with the cytokines TNF-α, IL-6 and oncostatin M down-regulated OATP1B1, OATP1B3, OATP2B1 and OAT2 expression, while IL-1β and IFN-γ repressed OATP1B1, OATP1B3 and OATP2B1 (Le Vee et al., 2008 Vee et al., , 2011a . A strength of these studies was the use of primary cells and it appears that there may be selectivity in the regulatory actions of particular cytokines on individual transporters. It would now be useful to obtain additional mechanistic information to assess whether transporter trafficking mediators are responsive to cytokines. This would enable follow-up studies in which transporter responses to pathological infections could be assessed.
In rats the renal excretion of organic anions is reduced during sepsis, which is a lethal inflammatory syndrome, and following ischaemia-reperfusion (IR) injury (Hocherl et al., 2009) . Sepsis decreased transporter expression by altering the transcriptional mechanism involving IL-6, STAT3, and HNF1α (Andrejko et al., 2008) . Thus, production of the cytokine IL-6 activates the JAK-STAT3 pathway, which down-regulates HNF1α and leads to decreased OAT1 expression at the basolateral membrane of proximal tubular cells. There was evidence of impaired trafficking of OAT1 in IR injury. Using confocal microscopy the transporter was expressed diffusely in cytoplasm of kidney cells subjected to IR (Kwon et al., 2008) . In a similar study, endotoxaemia caused a time-and dose-dependent decrease of OAT1 and OAT3 expression that was prevented by inhibition of COX-2 (Hocherl et al., 2009 ). This finding suggests that prostanoids down-regulate OATs during LPS-induced acute renal injury (Hocherl et al., 2009) .
Some transporters may be functionally important in alleviating pathological toxicities. Uraemic toxins accumulate in patients with chronic kidney diseases (Suzuki et al., 2011) . When OATP4C1 was expressed in a humanized transgenic rodent model the excretion of uraemic toxins was increased, which relieved pathogenic processes in uraemic kidney (Suzuki et al., 2011) . In an animal model of chronic renal failure, oat1 and oat3 were relocated from basolateral membranes of proximal tubule cells in controls, to show a more cytoplasmic distribution in kidney after ischaemia/reperfusion (Matsuzaki et al., 2007 (Matsuzaki et al., , 2008 Schneider et al., 2007) .
Hepatic IR injury frequently precedes cholestatic liver disease (Tanaka et al., 2006) . Bacterial LPS is a common mediator of inflammation-induced cholestasis in humans and has also been used in animal studies to initiate cholestasis by increasing the synthesis of pro-inflammatory cytokines such as TNF-α. Cytokines released by Kupffer cells following hepatic IR injury may subsequently regulate hepatic transporter expression possibly involving a decrease in nuclear HNF1α (Tanaka et al., 2006) . Support for this comes from the finding that pretreatment with gadolinium chloride to deplete Kupffer cells blocked the increase in serum bile acids in IR injury, attenuated TNF-α production and decreased hepatic transporter expression (Tanaka et al., 2006) .
Unchanged or higher levels of mRNAs encoding hepatic OATP1A2 (Kullak-Ublick et al., 1997; Keitel et al., 2005) , but lower levels of OATPs 1B1 and 1B3 (Keitel et al., 2005) , have been reported to occur in patients with liver disease. Serum bile acids accumulate in hepatic cholestasis and activate the FXR, which promotes the transcription of FXR-responsive genes that include the negative transcription factor small heterodimer partner 1 (SHP; Figure 2B ). SHP represses HNF4α, which then decreases HNF1α availability. The HNFs are activators of the bile acid-transporters OATP1B1 and OATP1B3. Down-regulation of these transporters decreases the uptake of bile acids into hepatocytes . As might be anticipated, bile acids also suppress other human transporters that are regulated by HNF4α (Popowski et al. 2005) and HNF1α (Jung and Kullak-Ublick, 2003) . There is evidence that this mechanism also has relevance for drug therapy. Intake of the bile acid ursodeoxycholic acid by 12 healthy volunteers increased the systemic availability of the OATP1B1 substrate rosuvastatin (to~150% of control), which is consistent with impaired hepatic uptake and a 30% decrease in overall rosuvastatin clearance .
Altered drug disposition in diabetes and fatty liver injury
A recent study investigated the renal and hepatic expression of Oats and Oatps in the Ins2Akita murine model of type I (insulin-dependent) diabetes that carries a point mutation in the insulin-2 gene and that exhibits both hyperglycaemia and renal complications (Xu et al., 2015) . Renal expression of the murine counterparts of the human drug influx transporters, namely mOatp1a1, mOatp1a6, mOat3 and mOat5, was decreased at the mRNA and protein levels, while mOatp1a4 was increased in livers of diabetic mice (Xu et al., 2015) . In a similar study, Phatchawan et al. (2014) reported the down-regulation of rOAT3 in streptozotocin-induced insulin-dependent diabetic rats that was apparently associated with activation of the NF-κB pathway and translocation from the plasma membrane. In uncontrolled diabetes the relocation of rOAT3 from the cell surface to the cytoplasmic compartment was reversed by insulin administration. The loss of the membrane expression of rOAT3 was attributed to activation of PKC and NF-κB signalling. As discussed, PKC activation has been associated with increased internalization of several OATs/OATPs from that plasma membrane in cells so it is feasible this mechanism is involved in the impairments involved in models of type I diabetes.
The incidence of metabolic syndrome is increasing in western society, as evidenced by increasing obesity, type II (non-insulin-dependent) diabetes and non-alcoholic fatty liver disease, which can progress to the inflammatory condition non-alcoholic steatohepatitis (NASH). The expression of drug transporters is altered in several experimental models of fatty liver disease. Expression of Oatp1a1 protein was decreased in rats with fatty liver induced by prolonged intake of a high-fat diet and NASH induced by intake of a methionine/choline-deficient diet for eight weeks (Fisher et al., 2009) . Oatp1b2 was also decreased in the NASH model, but not in models of simple fatty liver (Fisher et al., 2009) . In other studies, hepatic Oatp1a4 protein was downregulated in genetic models of NASH (the ob/ob and db/db mice and the fa/fa rat; Canet et al., 2014) . The selective down-regulation of some transporters in NASH models could be due to the increased inflammation in these livers (Fisher et al., 2009) . Important information on the expression of human OATPs in liver disease has emerged recently. Clarke et al. (2017) reported decreased glycosylation of OATPs 1B1, 1B3 and 2B1 in livers from patients with non-alcoholic fatty liver disease, which might be due to decreased expression of N-glycan biosynthetic enzymes. Using a proteomics approach Wang et al. (2016) reported an increase in hepatic OATP2B1 in cirrhosis induced by hepatitis C infection, but not alcohol intake, while the expression of both OATP1B1 and OATP1B3 was decreased in cirrhosis induced by alcohol, but not by hepatitis C. These findings could be relevant for understanding how the more severe forms of liver disease, such as NASH, cirrhosis and hepatocellular carcinoma, develop as part of the metabolic syndrome and complicate drug treatment. These liver injuries are known to selectively decrease the expression of CYPs and transporters that have important roles in drug biotransformation, disposition and pharmacokinetics (Murray et al., 1987; 1991; Oswald et al., 2001; Wlcek et al., 2011; Brenner et al., 2015) .
Summary and conclusions
An increasing number of studies have identified complex post-translational mechanisms in the regulation of human OATs and OATPs. Correct membrane delivery is essential for optimal transport function of mature glycosylated proteins while continuous recycling processes enable the Trafficking mechanisms for OATs and OATPs BJP fine-tuning of plasma membrane expression. Internalization of transporter proteins is regulated by phosphorylation and ubiquitination that modulate caveloin-and clathrinmediated endocytosis. Recent evidence has also identified the colocation of OATPs with specific Rab GTPase isoforms and demonstrated that PDZ proteins modulate the subcellular trafficking of OATs and OATPs in particular cell types. It is also emerging that there is interplay between PDZ proteins and kinesin and dynamin molecular motors that regulate the vesicular targeting of transporter proteins to specific subcellular regions. As the involvement of each of these processes in transporter trafficking develops, additional detail will emerge to delineate why specific transporters are expressed in particular cell types. The fate of transporters in cells will be expanded with greater information on phosphorylation and ubiquitination events and targeting to recycling endosomes and degradation.
It is now clear that multiple trafficking mediators are disrupted in disease states. Vesicular trafficking is increased in some viral infections (Trahey et al., 2012) ; this promotes viral replication but also has the potential to modulate trafficking of host proteins, including transporters. Bridge et al. (2001) reported dysregulation of clathrin in myofibroblastic tumours and there is increasing evidence that motor proteins such as KifC1 and KifC3 are associated with aberrant lung and breast cancer cell behaviour (Liu et al., 2013) . Rab GTPases are regulated in multiple cell types by cytokines that are released during infections (Pei et al., 2012) while specific isoforms are up-regulated in tumours, which may have pathogenic roles in tumour invasion and metastasis (Li and Marlin, 2015) . Rabs are also dysregulated in diabetes, systemic lupus erythomatosus, Alzheimer's disease and Downs' syndrome. Indeed, Rab7 and Rab11 isoforms, which are already implicated in the trafficking of certain OATPs, are altered in certain neurological diseases, cancers and obesity (Agola et al., 2011; Nakano et al., 2012) . Finally, the overexpression of PKCα and CK2 has been reported in human breast tumours and other cancers (Münstermann et al., 1990; Lahn et al., 2004) . The interpretation of how these trafficking mediators are dysregulated in disease could provide valuable information to account for the altered expression of drug-influx transporters in those conditions. Detailed analysis of the expression of transporter proteins at the plasma membrane of cells, in response to exogenous toxicologic and pathological stimuli, is now warranted. Appropriate reagents and techniques are available. The use of membrane-impermeable biotinylation reagents has provided valuable information on relative changes in cell surface expression (Zhou et al., 2004; Zhou et al., 2010) . The use of proteomics has recently enabled more precise measurements of transporter isoforms in isolated plasma membranes, including post-translational modifications (Prasad and Unadkat, 2014; Qiu et al., 2014; Wang et al., 2016) . Further application of these methods in timedependent studies could provide important quantitative information on how the expression of mature transporter isoforms at the plasma membrane changes in response to a range of stimuli. Such studies could provide insight into how disease processes alter transporter expression and could inform the underlying mechanisms. In addition, practical information could be provided to inform appropriate drug selection for the treatment of these pathological states.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015 /16 (Alexander et al., 2015a .
